List of Gloperba drug patents

Gloperba is owned by Romeg.

Gloperba contains Colchicine.

Gloperba has a total of 4 drug patents out of which 0 drug patents have expired.

Gloperba was authorised for market use on 30 January, 2019.

Gloperba is available in solution;oral dosage forms.

Gloperba can be used as a method of prophylactic treatment of gout flares in adults comprises administering to a patient a liquid colchicine oral solution.

The generics of Gloperba are possible to be released after 20 December, 2037.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10383820 ROMEG Colchicine drug-to-drug interactions
Nov, 2036

(13 years from now)

US10383821 ROMEG Colchicine drug-to-drug interactions
Nov, 2036

(13 years from now)

US9907751 ROMEG Composition and method of use of colchicine oral liquid
Nov, 2036

(13 years from now)

US10226423 ROMEG Colchicine drug-to-drug interactions
Dec, 2037

(14 years from now)

Drugs and Companies using COLCHICINE ingredient

Market Authorisation Date: 30 January, 2019

Treatment: A method of prophylactic treatment of gout flares in adults comprises administering to a patient a liquid colchicine oral solution

Dosage: SOLUTION;ORAL

How can I launch a generic of GLOPERBA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in